Erinacines, Hericenones, and Which Lion's Mane the Trials Actually Used
The two headline Lion's Mane compound families sit in different tissues. Hericenones failed a human-cell NGF assay. What a CoA should carry.
Executive Summary
Lion's Mane sells on a neurotrophic story. That story rests on two compound families, and they do not live in the same part of the mushroom.
Erinacines are cyathane-type diterpenoids, and they are reported from the mycelium. Hericenones are aromatic, largely lipophilic resorcinol derivatives, and they sit in the fruiting body[1].
That is not a footnote. In a validated UHPLC-UV survey published this year, a commercial mycelium product carried 0.244 mg/g erinacine A with hericenones below the limit of quantification — while across five fruiting-body finished products, erinacine A was not detected at all[1].
So a clinical result generated on one tissue does not carry to the other. In these samples the marker compound was not merely lower in the other tissue. It was not detected.
And the evidence behind the two families is not symmetric. Erinacine A has rodent pharmacokinetics, blood-brain-barrier data, and a 49-week human trial built around a declared erinacine A content. Hericenones C, D and E failed to induce NGF gene expression in the human cell assay used to look for it[2].
1. Two families, two tissues, and real numbers
The 2026 method paper is useful to a Lion's Mane buyer because it puts a validated number against ten markers in commercial materials[1]. It is a single-laboratory study with a small number of products.
| Material | Erinacine A | Hericenone C | Ergosterol |
|---|---|---|---|
| Mycelium finished product (MFP-01) | 0.244 mg/g | below LOQ | below LOQ |
| Fruiting body raw material (Raw-01) | not detected | 0.135 mg/g | 1.651 mg/g |
| Fruiting body product (FFP_4) | not detected | 0.0048 mg/g | 0.520 mg/g |
| Fruiting body product (FFP_3) | not detected | 0.0988 mg/g | 1.200 mg/g |
| Fruiting body product (FFP_5) | not detected | 0.241 mg/g | 1.798 mg/g |
| Fruiting body product (FFP_7) | not detected | 0.294 mg/g | 1.418 mg/g |
Two findings matter commercially.
The tissue split is clear in these samples. Erinacine A appears in the mycelial product and nowhere else. Hericenones appear in fruiting-body material and are below quantification in the mycelial one. This is the compound distribution the literature describes, measured rather than asserted.
The fruiting-body spread is wide. Hericenone C runs from 0.0048 mg/g to 0.294 mg/g across five commercial fruiting-body products — roughly a 60-fold range. The authors attribute this to strain and harvest stage, and note plainly that the frequency of markers falling below the limit of quantification in commercial products "highlights significant variability in the market and the urgent need for standardized quantification"[1].
A 60-fold range means two products with identical labels are not the same ingredient. If your specification says "Lion's Mane fruiting body extract" and nothing else, you have specified almost nothing.
2. The hericenone problem
Hericenones are the reason the fruiting body has a neurotrophic reputation. The foundational work — Kawagishi's group, from 1990 onward — isolated hericenones C to H and reported that they stimulate NGF biosynthesis[3].
In 2008, a different group tested this directly in a human cell system. Ethanol extracts of four edible mushrooms were screened for NGF gene expression in 1321N1 human astrocytoma cells. Only H. erinaceus extract promoted NGF mRNA expression, and it did so concentration-dependently. The extract worked.
Then they tested the compounds. The paper's conclusion:
H. erinaceus contains active compounds that stimulate NGF synthesis via activation of the JNK pathway; these compounds are not hericenones[2].
Hericenones C, D and E failed to promote NGF gene expression in that system.
This is a real contradiction in the literature, not a settled question. The two result sets use different cell systems and different endpoints, and neither has been retracted. But it means the mechanistic claim most commonly attached to fruiting-body Lion's Mane — "hericenones stimulate NGF" — has a published negative alongside its positives[2].
There is a second caution. In 2024, Kawagishi's own group reported that a compound previously isolated from the fruiting body and assigned as 3-hydroxyhericenone F did not match the synthesised material; the actual structure was a substituted 2,3-dihydrobenzofuran, renamed hericenone Z[3]. At least one named hericenone structure has therefore been revised decades into the series.
3. What erinacine A actually has behind it
The erinacine file is thinner in volume and stronger in kind.
A 2021 study in Sprague-Dawley rats dosed H. erinaceus mycelial extract orally at 2.381 g/kg body weight (equivalent to 50 mg/kg erinacine A) against a 5 mg/kg intravenous dose. Absolute oral bioavailability of erinacine A came out at 24.39%. Erinacine A was detected in brain tissue 1 h after oral dosing, peaking at 8 h, with an unbound brain-to-blood ratio close to unity — consistent with passive diffusion across the blood-brain barrier. Faeces was the major elimination route[4].
That is a specific, quantified result, and it is the main difference in evidence between the two compound families. We did not find an equivalent blood-brain-barrier dataset for hericenones.
Two limits belong with it. It is a rodent study. And the dose used to generate it — 50 mg/kg erinacine A — is not the dose in anyone's capsule, as the next section shows.
4. What the human trials actually used
Three human studies carry most of the weight. They used three different materials.
| Study | Material | Daily dose | Marker declared | Completers | Duration |
|---|---|---|---|---|---|
| Mori 2009[6] | Fruiting body dry powder | 3.0 g (96% powder) | none reported | 30 (15/15) | 16 weeks |
| Li 2020[5] | Erinacine A-enriched mycelium | 1.05 g → 5.25 mg erinacine A | erinacine A 5 mg/g by HPLC | 41 (20/21) | 49 weeks |
| Surendran 2025[7] | Fruiting body 10:1 extract | 3 g, single dose | not reported | 18 (crossover) | acute, 90 min |
Mori 2009 is the study most often cited for Lion's Mane and cognition. Fifty- to eighty-year-old Japanese adults with mild cognitive impairment took twelve 250 mg tablets a day for 16 weeks. Scores on a scale based on the Revised Hasegawa Dementia Scale were significantly higher than placebo at weeks 8, 12 and 16, rose with duration of intake, and fell significantly four weeks after intake stopped[6]. The washout adds weight to the result.
What it does not do is tell you what was in the tablets. No hericenone content, no marker assay, no extract ratio. Li et al. make the same observation about it: the active constituents and representative markers of those tablets "have not been extensively addressed"[5]. So the trial supports "this material worked" and cannot support "hericenones worked" or "your fruiting-body powder will work."
Li 2020 is the only trial designed around a declared marker: three 350 mg capsules per day of mycelium standardised to 5 mg/g erinacine A — 5.25 mg erinacine A daily — for 49 weeks in mild Alzheimer's disease. The dose was derived by converting a mouse study to a human equivalent under FDA guidance, not established independently in humans[5].
Its results need reading carefully, because the summary version circulating in trade press is not what the paper reports:
| Endpoint | What the paper found |
|---|---|
| MMSE | Rose within the treatment group, 21.75 → 23.2, p = 0.035. All between-group pairwise comparisons were non-significant (p > 0.05). |
| CASI | Treatment trend up (p = 0.058), placebo trend down (p = 0.064). No significant between-group difference. |
| IADL | Between-group difference significant at week 49 only (6.7 vs 5.0, p = 0.012). |
| Contrast sensitivity | Between-group difference at week 49 in one eye (p = 0.046). |
A within-group change with no between-group difference is a weak result. The target enrolment was at least 60; 68 were recruited, 49 randomised, 41 completed. The authors call it a pilot and say so. It is also worth knowing that the first author group is the Biotech Research Institute of Grape King Bio Ltd., which produces the erinacine A-enriched material — as it is on the 2021 pharmacokinetic paper[4][5].
Surendran 2025 is a negative acute result. Eighteen healthy 18-to-35-year-olds, 3 g of a 10:1 fruiting-body extract, crossover, assessed at 90 minutes. No significant effect on composite global cognitive function or mood. One individual test — a pegboard task — improved. The authors conclude any benefit "may be task or domain specific"[7].
5. What to specify
The practical consequence is that "Lion's Mane" is not a specification, and neither is "fruiting body" on its own.
| Line to specify | Why | Method |
|---|---|---|
| Tissue: fruiting body / mycelium / ratio | Determines which compound family can be present at all | Declaration + marker confirmation |
| Erinacine A, mg/g | The only marker with BBB and dose-anchored human data behind it | UHPLC-UV, LOQ ≈ 0.64 µg/mL |
| Hericenone C (and D, E), mg/g | Controls the 60-fold fruiting-body spread | UHPLC-UV, LOQ ≈ 9.3 µg/mL |
| Ergosterol, mg/g | Compositional marker for fungal tissue; 0.5–1.8 mg/g in the fruiting-body samples above | UHPLC-UV |
| Starch / grain residue | Detects mycelium-on-grain carried as "mushroom" | Separate assay |
| Species identity | Confirms the organism is H. erinaceus | DNA barcoding |
Two notes on that table.
Ergosterol is a compositional marker for fungal material[1]. In the fruiting-body samples above it ran at 0.5–1.8 mg/g; in the mycelium product it was below the limit of quantification. It will not tell you which Hericium you have, but a low ergosterol reading on a product sold as fruiting-body material is worth a question.
And the whole set now runs on one method. The 2026 validation quantifies hericenones, hericenes, erinacine A and ergosterol in a single 38.5-minute UHPLC-UV run at 283 nm, without mass spectrometry — inter-day RSD 1.1% to 5.7%[1]. A validated routine method for these markers now exists, so it is reasonable to ask a supplier for them.
This is a technical purchasing guide, not a health claim and not regulatory advice. Nothing here establishes that Lion's Mane in any form produces a cognitive benefit in humans; the trials described are small, and the largest reports a non-significant between-group result on its principal cognitive endpoint. Marker content should be treated as an identity and consistency control, not as evidence of efficacy. Confirm method suitability and limits of quantification with your own laboratory before writing any figure into a specification.
Where Viridia sits on this
Viridia's Lion's Mane is produced from cultivated Hericium erinaceus fruiting bodies under hot-water extraction, with batch-level polysaccharide and beta-glucan testing, microbiological screening and heavy metals analysis on every lot.
See the Lion's Mane specification →
Request marker profile and batch documentation →
References
[1] Tang et al. (2026). Simultaneous UHPLC-UV Determination of Hericenones, Hericenes, Erinacines and Ergosterol in Hericium erinaceus Raw Materials or Products. Molecules 31(3):569. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12899107/
[2] Mori et al. (2008). Nerve Growth Factor-Inducing Activity of Hericium erinaceus in 1321N1 Human Astrocytoma Cells. Biological and Pharmaceutical Bulletin 31(9):1727-1732. Retrieved from https://www.jstage.jst.go.jp/article/bpb/31/9/31_9_1727/_article
[3] Wang et al. (2024). Uncovering Hericenones from the Fruiting Bodies of Hericium erinaceus through Interdisciplinary Collaboration. Journal of Natural Products 88(1):80-85. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11773572/
[4] Tsai et al. (2021). Preclinical Bioavailability, Tissue Distribution, and Protein Binding Studies of Erinacine A, a Bioactive Compound from Hericium erinaceus Mycelia Using Validated LC-MS/MS Method. Molecules 26(15):4510. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8347307/
[5] Li et al. (2020). Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Frontiers in Aging Neuroscience 12:155. Retrieved from https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2020.00155/full
[6] Mori et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research 23(3):367-372. Retrieved from https://pubmed.ncbi.nlm.nih.gov/18844328/
[7] Surendran et al. (2025). Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition 12:1405796. Retrieved from https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1405796/full
More from Viridia
Keep exploring
Wild-Harvested Blue-Green Algae Is Often Not Spirulina
The main wild-harvested blue-green algae product, from Upper Klamath Lake, is a different genus, harvested from a lake where a microcystin producer blooms. Cultivated Limnospira has no genetic capacity to make microcystins. Any microcystin in a spirulina lot comes from a contaminant, and 'cultivated' is not a specification on its own.
Phycocyanin's Antioxidant Mechanism: Where the Biliverdin Reductase Story Is Established, and Where It Stops
The phycocyanobilin-to-phycocyanorubin pathway is real enzymology. The leap from that pathway to an antioxidant claim on a finished product crosses four steps, and only the first is settled. A dose-arithmetic check on what the rodent data would actually require.
What "Ganoderma lucidum" Actually Means on a Reishi CoA
Almost no commercial reishi is Ganoderma lucidum. Three binomials, an unresolved nomenclature dispute, a measured chemical difference, and what to specify instead.